BackHofseth BioCare ASA Overview

Hofseth BioCare ASA Receivables

Hofseth BioCare ASA's receivables is $30M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$30.16M
↑ 16.15% YoYΔ $4.19M vs prior year quarter

Peer trimmed avg / median

Loading

Hofseth BioCare ASA Receivables History

Loading

Hofseth BioCare ASA vs. peers: Receivables Comparison

Loading

Hofseth BioCare ASA Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Hofseth BioCare ASA (HOFBF) FAQ

The latest receivables for HOFBF is $30M as of June 2026. That compares with $26M in the prior-year period — up 16.2% year over year. Investors often review this figure alongside Hofseth BioCare ASA's historical trend and sector peers before judging valuation or financial health.

Over the past year, HOFBF's receivables moved from $26M to $30M — a 16.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hofseth BioCare ASA's operating scale or balance-sheet position.

A receivables figure of $30M for HOFBF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting HOFBF's receivables ($30M), review year-over-year change from $26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.